A1 Alkuperäisartikkeli tieteellisessä aikakauslehdessä

Combined genetic and chemical screens indicate protective potential for EGFR inhibition to cardiomyocytes under hypoxia

Julkaisun tekijät: Heliste Juho, Jokilammi Anne, Vaparanta Katri, Paatero Ilkka, Elenius Klaus

Julkaisuvuosi: 2021

Journal: Scientific Reports

Tietokannassa oleva lehden nimi: Scientific reports

Lehden akronyymi: Sci Rep

Volyymi: 11

ISSN: 2045-2322

eISSN: 2045-2322

DOI: http://dx.doi.org/10.1038/s41598-021-96033-z

The return of blood flow to ischemic heart after myocardial infarction causes ischemia-reperfusion injury. There is a clinical need for novel therapeutic targets to treat myocardial ischemia-reperfusion injury. Here we screened for targets for the treatment of ischemia-reperfusion injury using a combination of shRNA and drug library analyses in HL-1 mouse cardiomyocytes subjected to hypoxia and reoxygenation. The shRNA library included lentiviral constructs targeting 4625 genes and the drug library 689 chemical compounds approved by the Food and Drug Administration (FDA). Data were analyzed using protein-protein interaction and pathway analyses. EGFR inhibition was identified as a cardioprotective mechanism in both approaches. Inhibition of EGFR kinase activity with gefitinib improved cardiomyocyte viability in vitro. In addition, gefitinib preserved cardiac contractility in zebrafish embryos exposed to hypoxia-reoxygenation in vivo. These findings indicate that the EGFR inhibitor gefitinib is a potential candidate for further studies of repurposing the drug for the treatment of myocardial infarction.

Ladattava julkaisu

This is an electronic reprint of the original article.
This reprint may differ from the original in pagination and typographic detail. Please cite the original version.

Last updated on 2021-22-09 at 15:05